Could this new vaccine stop shingles for years?

NCT ID NCT07293065

Ongoing ⭐️ VACCINE ⭐️ Sponsor: MAXVAX Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who develops shingles over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant Zoster Vaccine (CHO Cell) with adjuvant
What this could lead to: If successful, this vaccine could provide long-term protection against shingles for adults 40 and older, reducing pain and complications.
What could go wrong: This is a large Phase 3 trial, but results are not yet available. The vaccine may not prove effective over the full 3 years, and side effects like injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER

Contacts and locations

Locations

Hebei Provincial Center for Disease Control and Prevention

Shijiazhuang, Hebei, 050021, China
Henan Center for Diseases Control and Prevention

Zhengzhou, Henan, 450016, China
Hubei Provincial Center for Disease Control and Prevention

Wuhan, Hubei, 430070, China
Yunnan Center For Disease Control and Prevention

Kunming, Yunnan, 650022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.